in a phase iii, 52-week study, the rates of response (a reduction of â‰¥4 points on the sle response index [sri]) at week 52 were 51% and 58% with belimumab 1 and 10 mg/kg/dose, respectively, versus 44% with placebo (both, p < 0.05).